JPWO2020092726A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020092726A5
JPWO2020092726A5 JP2021548563A JP2021548563A JPWO2020092726A5 JP WO2020092726 A5 JPWO2020092726 A5 JP WO2020092726A5 JP 2021548563 A JP2021548563 A JP 2021548563A JP 2021548563 A JP2021548563 A JP 2021548563A JP WO2020092726 A5 JPWO2020092726 A5 JP WO2020092726A5
Authority
JP
Japan
Prior art keywords
pyrrolo
pyrimidin
pyrazol
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021548563A
Other languages
English (en)
Japanese (ja)
Other versions
JP7431845B2 (ja
JP2022513409A (ja
JP2022513409A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059099 external-priority patent/WO2020092726A1/en
Publication of JP2022513409A publication Critical patent/JP2022513409A/ja
Publication of JPWO2020092726A5 publication Critical patent/JPWO2020092726A5/ja
Publication of JP2022513409A5 publication Critical patent/JP2022513409A5/ja
Application granted granted Critical
Publication of JP7431845B2 publication Critical patent/JP7431845B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021548563A 2018-10-31 2019-10-31 血液疾患の治療のための併用療法 Active JP7431845B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753409P 2018-10-31 2018-10-31
US62/753,409 2018-10-31
PCT/US2019/059099 WO2020092726A1 (en) 2018-10-31 2019-10-31 Combination therapy for treatment of hematological diseases

Publications (4)

Publication Number Publication Date
JP2022513409A JP2022513409A (ja) 2022-02-07
JPWO2020092726A5 true JPWO2020092726A5 (https=) 2022-11-08
JP2022513409A5 JP2022513409A5 (https=) 2022-11-08
JP7431845B2 JP7431845B2 (ja) 2024-02-15

Family

ID=68655663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548563A Active JP7431845B2 (ja) 2018-10-31 2019-10-31 血液疾患の治療のための併用療法

Country Status (14)

Country Link
US (1) US11324749B2 (https=)
EP (1) EP3873433A1 (https=)
JP (1) JP7431845B2 (https=)
KR (1) KR20210109522A (https=)
CN (1) CN113490484B (https=)
AU (1) AU2019374072A1 (https=)
CA (1) CA3117969A1 (https=)
EA (1) EA202191170A1 (https=)
IL (1) IL282643B2 (https=)
MA (1) MA54077A (https=)
MX (1) MX2021004946A (https=)
PH (1) PH12021550965A1 (https=)
SG (1) SG11202104321PA (https=)
WO (1) WO2020092726A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104918945B (zh) * 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CA3097025A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
EP4041204A1 (en) 2019-10-10 2022-08-17 Incyte Corporation Biomarkers for graft-versus-host disease
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
WO2009064835A1 (en) 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CA3121743A1 (en) 2009-01-15 2010-07-22 Incyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションIncyte Corporation ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
KR101921850B1 (ko) 2009-10-09 2018-11-23 인사이트 홀딩스 코포레이션 3-(4-(7H-피롤로〔2,3-d〕피리미딘-4-일)-1H-피라졸-1-일)-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
EP2536729A1 (en) 2010-02-18 2012-12-26 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CA2827673C (en) 2011-02-18 2020-10-27 Novartis Pharma Ag Mtor/jak inhibitor combination therapy
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN104918945B (zh) 2012-11-01 2018-01-05 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
SMT201900223T1 (it) 2013-05-17 2019-07-11 Incyte Corp Sale di bipirazolo come inibitore di jak
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
CN105555313A (zh) 2013-08-20 2016-05-04 因赛特公司 在c-反应蛋白水平较高的实体肿瘤患者中的存活益处
JP6576941B2 (ja) * 2014-02-28 2019-09-18 インサイト・コーポレイションIncyte Corporation 骨髄異形成症候群の治療のためのjak1阻害剤
CN106687462A (zh) 2014-04-30 2017-05-17 因赛特公司 Jak1抑制剂的制备方法以及其新形式
EP3148545B1 (en) * 2014-05-28 2023-03-15 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
KR102399848B1 (ko) 2016-10-03 2022-05-19 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 신규한 jak1 선택적 억제제 및 그 용도
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
IL311485B1 (en) 2018-02-16 2026-01-01 Incyte Corp JAK1 pathway inhibitors for the treatment of cytokine-related disorders
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CA3097025A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
CA3123596A1 (en) 2018-12-19 2020-06-25 Incyte Corporation Jak1 pathway inhibitors for the treatment of gastrointestinal disease
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Similar Documents

Publication Publication Date Title
JP2017506659A5 (https=)
JP2021519775A5 (https=)
RU2472509C2 (ru) Способ лечения артрита
EP3661560B1 (en) Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
AU2016204396B2 (en) Methods of treatment using selective Bcl-2 inhibitors
JP2022189853A5 (https=)
JP2009542639A5 (https=)
JP2015500862A5 (https=)
JP2019517596A5 (https=)
JP2009542638A5 (https=)
JP2009513575A5 (https=)
JP7431845B2 (ja) 血液疾患の治療のための併用療法
CN111643496A (zh) 使用mek抑制剂的方法
JPWO2020092726A5 (https=)
CN110505884A (zh) 抗癌组合疗法
US11660301B2 (en) Combination of ATR kinase inhibitors with PARP inhibitors
JP2018526391A5 (https=)
PH12021551449A1 (en) Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
AU2018354777A1 (en) Novel Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors
US20100087436A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2023159050A (ja) Ccr4アンタゴニスト
US20230405015A1 (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
JPWO2021214117A5 (https=)
JPWO2020249791A5 (https=)